Revolo Biotherapeutics Announces Completion of Phase 2a Trial of ‘1104 in Allergic Disease
March 27, 2023Business Services
NEW ORLEANS, LA and CAMBRIDGE, England, March 27, 2023 – Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing …
Statement Following Jounce Therapeutics Announcement of a Definitive Merger Agreement with Concentra Biosciences and Withdrawal of their Recommendation for the Business Combination with Redx
March 27, 2023Business Services
Alderley Park, UK 27 March 2023 Redx Pharma (“Redx”, AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing …
MHRA Grants Conditional Marketing Authorisation in Great Britain to CSL’s HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Haemophilia B
March 27, 2023Business Services
This medicine is subject to additional monitoring.This will allow quick identification of new safety information.
Avacta to present pre-clinical data on AVA3996 at the American Association for Cancer Research Annual Meeting
March 27, 2023Business Services
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces it will …
Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
March 27, 2023Business Services
Leiden, The Netherlands, March 24, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the …
Novartis announces positive results from phase 3 trial of Kisqali for early breast cancer
March 27, 2023Research and Development
Novartis has announced positive results from its phase 3 NATALEE trial assessing Kisqali (ribociclib) along with endocrine therapy (ET) in …
Abberior installs new STED microscope at MBC BioLabs
March 27, 2023Medical Communications
Abberior has announced that it has placed a super-resolution STED microscope at MBC BioLabs, which is the leading San Francisco …
FDA releases draft of accelerated approval guidance for oncology therapeutics
March 27, 2023Medical Communications
The FDA has released a draft of new guidance for accelerated approval for oncology therapeutics, highlighting the need for stricter …
University of Leipzig and SiSaf partner over Bio-Courier targeted miRNA
March 27, 2023Medical Communications
SiSaf, an RNA delivery and therapeutics company, has announced a collaboration with the University of Leipzig to develop Bio-Courier targeted …
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights
March 24, 2023Business Services
NEW YORK and BERLIN, March 24, 2023 (GLOBE NEWSWIRE) — atai Life Sciences&
Announces publication of XF-73 nasal gel Phase 2 data in leading US journal Infection Control & Hospital Epidemiology Demonstrates significant reduction of nasal S. aureus in preoperative cardiac surgery patients
March 24, 2023Business Services
Brighton, United Kingdom – 24 March 2023 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the …
NICE recommends PTC Therapeutics’ gene therapy for NHS use
March 24, 2023Medical Communications
NICE has recommended PTC Therapeutics’ gene therapy to the NHS for the treatment of ultra-rare disease aromatic L-amino acid decarboxylase …
Creative Medical Technology files FDA ODD application for Brittle Type 1 diabetes
March 24, 2023Medical Communications
US-based biotech company Creative Medical Technology has announced that it has filed for the FDA’s Orphan Drug Designation (ODD) for …
European Commission delays release of major changes to pharma legislation
March 24, 2023Medical Communications
The European Commission (EC) has again delayed the release of its new proposal for changes to Europe’s pharma legislation. The …
NeuroRPM announces FDA clearance for AI monitoring app for Parkinson’s disease on Apple Watch
March 24, 2023Medical Communications
NeuroRPM has announced that it has received clearance from the FDA for its NeuroRPM device which uses AI and existing …
NICE publishes guidance recommending Bayer’s Kerendia® (finerenone) as an option for treating adult patients with chronic kidney disease associated with type 2 diabetes
March 23, 2023Business Services
Reading, 23rd March 2023 – Today, the National Institute for Health and Care Excellence (NICE) has published a new guidance …
SYMBICORT (budesonide/formoterol) TURBOHALER 200/6 APPROVED AS FIRST AND ONLY COMBINATION RELIEVER FOR MILD ASTHMA IN THE UK
March 23, 2023Business Services
London, UK, Thursday 23 March 2023 – AstraZeneca today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has …
BIAL appoints Max Bricchi as Chief Commercial Officer
March 23, 2023Business Services
BIAL has announced the appointment of Max Bricchi as Chief Commercial Officer (CCO) and Executive Board member. With responsibility for …
Sosei Heptares Confirms Changes to its Board and Executive Management Team at Annual Shareholders’ Meeting
March 23, 2023Business Services
Tokyo, Japan and Cambridge, UK, 23 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in …
PureTech Health and Royalty Pharma enter KarXT royalty agreement up to $500m
March 23, 2023Sales and Marketing
Royalty Pharma have acquired a $500m interest in PureTech’s royalty in Karuna Therapeutics’ KarXT, with $100m cash up front and …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
